These results are consistent irrespective of whether OVOL inhibits miR-200 or not (Figure 2, Figure S4), i.e. the ZEB/OVOL expression ratio regulates the transition point for both EMT and MET, for both breast cancer and prostate cancer. This evidence concerns the gene ZEB1 and prostate carcinoma.